Jason Haas Purchases Shares of Ligand Pharmaceuticals

On June 12, 2026, Jason Haas made a notable move by purchasing 4,000 shares of Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). The shares were acquired at an average price of $51.56, bringing the total transaction value to $206,240. This insider buying activity was not part of a pre-planned trading program.

Insider Buying and Selling at Ligand Pharmaceuticals Incorporated

Jason Haas was active on June 12, 2026, buying 4,000 shares at $51.56 each and selling 4,000 shares at a different price. Additionally, he sold 6,461 shares at $255.58. These transactions were not executed under a Rule 10b5-1 plan. In the days prior, Jason Aryeh sold 4,500 shares at $250 on June 11, and another 500 shares on June 10 at the same price. John LaMattina also sold 4,591 shares at $250.88 on June 10.

Other Institutional Activity in Ligand Pharmaceuticals

BlackRock, Inc. increased its stake in Ligand Pharmaceuticals by 21,692 shares, holding a total of 2,961,923 shares valued at approximately $591.3 million. Vanguard Portfolio Management LLC added 1,100,267 shares, now holding a total of 1,100,267 shares worth $219.7 million. Janus Henderson Group PLC boosted its holdings by 14,491 shares, ending with 1,009,891 shares valued at about $201.6 million. Invesco Ltd. significantly increased its position by 307,140 shares, bringing its total to 823,604 shares valued at $164.4 million.

Ligand Pharmaceuticals Stock Snapshot

Shares of Ligand Pharmaceuticals (NasdaqGM: LGND) traded at $256.09. The company has a market cap of approximately $5.12 billion and a P/E ratio of 33.27. Its 52-week range spans from $110.00 to $259.03, with a 50-day moving average of $226.13 and a 200-day moving average of $199.39. Ligand has a current ratio of 21.28, a quick ratio of 20.81, and a debt-to-equity ratio of 45.32.

Recent Earnings

In its most recent financial period, Ligand Pharmaceuticals reported revenue of $274.5 million, reflecting a growth rate of 14.1%. The company's net margin stood at 55.95%, with a return on equity of 17.13%. The next earnings announcement is expected on August 6, 2026.

Analysts Set New Price Targets

Analysts have been bullish on Ligand Pharmaceuticals. On May 8, 2026, RBC Capital maintained a 'buy' rating with a price target of $262. HC Wainwright & Co. also maintained a 'buy' rating with a target of $289 on April 30, 2026. Citigroup maintained its 'buy' rating with a target of $282 on April 15, 2026. The average price target among analysts is $277.60, based on 10 opinions.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated is a biotechnology company based in Jupiter, Florida. It focuses on developing and licensing pharmaceutical assets worldwide. The company offers a range of products for infectious diseases, oncology, and other medical conditions, including Pradefovir and EVOMELA. Led by CEO Todd C. Davis, Ligand employs 47 people.

Bottom Line

Jason Haas's purchase of Ligand Pharmaceuticals shares highlights insider confidence in the company. Investors often watch insider transactions for potential signals, though these actions are not definitive indicators of future stock performance. Ligand Pharmaceuticals remains a key player in the biotechnology sector, with a strong market presence and continued interest from institutional investors and analysts.